Market-access agreements for anti-cancer drugs
Authors:
Open Access
- 8 December 2014
- journal article
- research article
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 108 (5) , 166-170
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product ManufacturersApplied Health Economics and Health Policy, 2014
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013
- Optional copayments on anti-cancer drugsBMJ, 2013
- Patient access schemes in the new NHSBritish Journal of Healthcare Management, 2012
- Risk sharing agreements: What lessons from Italy?International Journal of Technology Assessment in Health Care, 2011
- Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersHealth Policy, 2010
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersBMC Health Services Research, 2010
- Access with Evidence Development SchemesPharmacoEconomics, 2010
- Funding the UnfundablePharmacoEconomics, 2010
- Efficacy, safety, and cost of new anticancer drugsBMJ, 2002